4300 El Camino Real
About RetrotopeRetrotope has created a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. The unique mechanism of Retrotope’s platform prevents cellular damage and recovers cellular function damaged by lipid peroxidation due to oxidative stress. Retrotope’s first product candidate, RT001, is being clinically tested in Friedreich’s ataxia (FA), a high value untreated fatal orphan disease. Retrotope’s transformational platform technology of stabilized lipid drugs has the potential to treat a wide variety of other mitochondrial myopathies, but also show promise for diseases such as Parkinson’s, Alzheimer’s, diabetic retinopathy, and others.
Founder and CEO: Robert J. Molinari
Founder and CSO: Mikhail S. Shchepinov
Please click here for Retrotope job opportunities.
7 articles with Retrotope
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)
Retrotope announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug for the treatment of Progressive SupraNuclear Palsy.
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)Three clinical trials centers now open for enrollment; two additional ones initiating
Retrotope announced that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the inherited ataxias.
Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients
Parkinson’s Institute and Clinical Center and Retrotope announced today a collaboration on a new drug therapy to treat patients with Progressive SupraNuclear Palsy.
FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (P...
11/2/2017Physicians collaborating with Retrotope previously received approval from the FDA to test RT001 in Expanded Access trials of two patients having Infantile Neuroaxonal Dystrophy.
Retrotope To Present First Human Data On Safety And Early Efficacy Of RT001 With Neurodegeneration At American Academy of Neurology Meeting
Retrotope And Collaborators To Present Poster At American Academy of Neurology On Stabilized PUFA Drug Efficacy In Multiple Alzheimer’s Models